InvestorNewsBreaks – GT Biopharma Inc. (NASDAQ: GTBP) Secures $27M in Underwritten Public Offering
GT Biopharma (NASDAQ: GTBP), focused on the development and commercialization of its disruptive, target-directed Natural Killer (“NK”) cell engager immunotherapy protein biologic platform technology: TriKE(TM) for cancer and infectious diseases, has closed an underwritten public offering of 4,945,000 units. According to the update, the offering includes an additional 645,000 units pursuant to the full exercise of the over-allotment option granted to the underwriters. GT Biopharma…